Неклассические кардиоваскулярные эффекты агонистов имидазолиновых рецепторов

Авторы

  • Юлия В. Степенко Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0002-7414-7326
  • Олеся В. Щеблыкина Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0003-0346-9835
  • Анна А. Пересыпкина Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0003-2829-9860
  • Вероника С. Шмигерова Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0003-2941-0241
  • Йомна Ахмед Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0003-2941-0241
  • Татьяна А. Денисюк Курский государственный медицинский университет ORCID logo https://orcid.org/0000-0003-0974-4818
  • Антон П. Даниленко Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0009-0001-2419-8109
  • Никита С. Ляпкалов Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0009-0004-7208-5055
  • Елена А. Шмыкова Белгородская областная клиническая больница святителя Иоасафа ORCID logo https://orcid.org/0009-0005-2983-0619
  • Людмила М. Даниленко Белгородский государственный национальный исследовательский университет ORCID logo https://orcid.org/0000-0001-6101-8712

DOI:

https://doi.org/10.18413/rrpharmacology.11.640

Аннотация

Введение. Имидазолиновые рецепторы представляют собой группу метаботропных рецепторов, активация которых сопряжена с изменением ряда функциональных параметров, включая гемодинамику (снижение артериального давления (АД), отрицательное хроно- и инотропное действие), метаболический обмен (снижение инсулинорезистентности, повышение уровня ЛПВП) и гемореологию (антиагрегантная активность). Кроме того, спектр молекулярно-фармакологических эффектов агонистов имидазолиновых рецепторов (АИР) включает противовоспалительную, антиоксидантную и антифибринолитическую активность.

Материалы и методы. Поиск источников литературы проводился с использованием баз данных PubMed и Google Scholar, включая тип статьи, как мета-анализ, рандомизированное контролируемое исследование, обзор.  Критерием включения была полная доступность данных, научная значимость и релевантность исследований.

Результаты и обсуждения. Экспериментальные исследования на животных позволили выявить такие эффекты АИР, как снижение степени гипертрофии левого желудочка (ГЛЖ) и экспрессии интерлейкинов. Опыт применения АИР в клинической практике позволил выявить их эффективность при лечении пациентов с хронической сердечной недостаточностью (ХСН) II-III класса по NYHA с фракцией выброса менее 40%, артериальной гипертензией (АГ) и микроальбуминурией.

Выводы. В целом, совокупность имеющихся на сегодняшний день данных, свидетельствует о высокой целесообразности включения имидазолиновых рецепторов в репертуар фармакологических мишеней, воздействие на которые может оказывать влияние не только на мягкие, но и на жесткие конечные точки при лечении кардиоваскулярной патологии. 

Графическая аннотация

Ключевые слова:

агонисты имидазолиновых рецепторов, кардиоваскулярный континуум, хроническая сердечная недостаточность, атеросклероз

Библиографические ссылки

Alahari SK, Lee JW, and Juliano RL (2000) Nischarin, a novel protein that interacts with the integrinα5 subunit and inhibits cell migration. The Journal of Cell Biology 15: 1141–1154. https://doi.org/10.1083/jcb.151.6.1141 [PubMed]

Alter P, Apelt S, Figiel JH, Rominger MB, Rupp H, and Heitmann J (2012) The missing link between heart failure and sleep disordered breathing: increased left ventricular wall stress. Intetnational Journal of Cardiology 157(2): 294-297. https://doi.org/10.1016/j.ijcard[PubMed]

Bousquet P, Feldman J, Tibirica E, Bricca G, Molines A, Dontenwill M, and Belcourt A (1989) New concepts on the central regulation of blood pressure. Alpha 2-adreno-ceptors and “imidazoline receptors’. American Journal of Medicine 87: 10-13. https://doi.org/10.1590/s0074-02761993000200024 [PubMed]

Bousquet P, Feldman J, and Schwartz J (1984) Central cardiovascular effects of alpha-adrenergic drugs: Differences between catecholamines and imidazolines. The Journal of Pharmacology and Experimental Therapeutics 230(1): 232-236. [PubMed]

Bousquet P, Hudson A, García-Sevilla JA, Jun-Xu L, and France CP (2020) Imidazoline receptor system: The past, the present, and the future. Pharmacological Reviews 72(1): 50-79. https://doi.org/10.1124/pr.118.016311 [PubMed]

Britov AN and Orlova OA (2006) Place of agonists imidazol(in)e receptors in arterial hypertension patients therapy. Russian Journal of Cardiology 11(1): 95-100. [in Russian]

Brunton L, Chabner B, and Knollman B (2011) Goodman and Gilman’s Pharmacological Basis of Therapeutics. McGraw-Hill Education, 295 p.

Bylund D and Martinez JR (1981) Postsynaptic localization of alpha 2-adrenergic receptors in rat submandibular gland. The Journal of Neuroscience 1(9): 1003-1007. https://doi.org/1523/JNEUROSCI.01-09-01003.1981[PubMed] [PMC]

Chaikijurajai T and Wilson Tang WH (2020) Reappraisal of inflammatory biomarkers in heart failure. Current Heart Failure Reports 17(1): 9-19. https://doi.org/10.1007/s11897-019-00450-1 [PubMed]

Chan SL and Morgan NG (1998) Sigma receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets. European Journal of Pharmacology 350 (2-3): 267-272. https://doi.org/10.1016/s0014-2999(98)00263-5 [PubMed]

Danilenko AP, Khentov AA, Kuznetsov AV, Shmigerova VS, Stepenko YuV, Tarasova AP, Yakushev VI, Boeva EV, Miller AV, Tatarenkova IA, Puzanova TV, Loboda YaV, Trashchenko AP, Gudyrev OS, Motailo AL, Kuzichkin VN, Milashechko VN, and Danilenko LM (2025) Predictive analysis and prediction of the main molecular targets for the N-acetyl-6-aminohexanoate derivative. Research Results in Pharmacology 11(2): 73–85. https://doi.org/10.18413/rrpharmacology.11.560

Diamant S, Eldar-Geva T, and Atlas D (1992) Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. British Journal of Pharmacology 106 (1): 101–108. https://doi.org/10.1111/j.1476-5381.1992.tb14300.x[PMC]

Dickstein K, Manhenke C, Aarsland T, Kopp U, McNay J, and Wiltse C (1999) Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American of Journal Cardiology83(12):1638-1644. https://doi.org/1016/s0002-9149(99)00170-8 [PubMed]

Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, and Johnson GG (1995) I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Annals of the New York Academy of Sciences 763: 22–42. https://doi.org/10.1111/j.1749-6632.1995.tb32388.x [PubMed]

Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjostedt E, Lundberg E, Al-Khalili C, Skogs M, Ottosson J, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular Cellular Proteomics 13: 397-406. https://doi.org/10.1074/mcp.M113.035600 [PubMed]

Feher A, Toth VE, Al-Khrasani M, Balogh M, Lazar B, Helyes Z, Gyires K, and Zadori ZS (2017) Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology 25(1): 107-118. https://doi.org/10.1007/s10787-016-0299-7[PubMed]

Gasparik V, Greney H, Schann S, Feldman J, Fellmann L, Ehrhardt JD, and Bousquet P (2015) Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I2 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome. Journal of Medicinal Chemistry 58 (2): 878-887. https://doi.org/10.1021/jm501456p [PubMed]

Girgis I, Chakko S, de Marchena E, Jara C, Diaz P, Castellanos A, and Myerburg RJ (1998) Effect of clonidine on heart rate variability in congestive heart failure. Journal of the American College of Cardiology 82(3): 335-337. https://doi.org/11016/s0002-9149(98)00329-4. [PubMed]

Gongadze NV, Antelava NA, and Kezeli TD (2008) Imidazoline receptors. Georgian Medical News 44(7): 160-161. [PubMed]

Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, Matsui A, Katsume A, Yamaguchi S, Nishikawa K, Isoda K, Riches D, Matoba S, Okigaki M, and Matsubara H (2009) Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circulation Research 105(11): 1149-1158. https://doi.org/10.1161/circresaha.109.208199[PubMed]

Karlafti EF, Hatzitolios AI, Karlaftis AF, Baltatzi MS, Koliakos GG, and Savopoulos CG (2013) Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. Journal of Pharmacy and Bioallied Sciences 5(4): 253–256. https://doi.org/4103/0975-7406.120067 [PubMed]

Kawai T, Forrester SJ, O’Brien S, Baggett A, Rizzo V, and Eguchi S (2017) AT1 receptor signaling pathways in the cardiovascular system. Pharmacological Research 125: 4-13.https://doi.org/1016/j.phrs.2017.05.008 [PubMed]

Kerckhoven R, Veen TA, Boomsma F, Saxena PR, and Schoemaker RG (2000) Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. European Journal of Pharmacology 397(1): 113-120. https://doi.org/10.1016/s0014-2999(00)00232-6 [PubMed]

Lee J, Chen W, Wu H-T, Lin K, and Cheng J (2011) Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats. Hormone and Metabolic Research 43(1): 26–30. https://doi.org/10.1055/s-0030-1267169 [PubMed]

Li G, Regunatham S, Barrow C, Eshraghi J, Cooper R, and Reis DJ (1994) Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263(5): 966-969. https://doi.org/10.1126 / science.7906055 [PubMed]

Lijnen P, Petrov V, Rumilla K, and Fagard R (2002) Stimulation of collagen gel contraction by angiotensin II and III in cardiac fibroblasts. Journal of the Renin-angiotensin-aldosterone-System: JRAAS 3(3): 160-166. https://doi.org/10.3317/jraas.2002.036 [PubMed]

Lin MH, Hsu CC, Lin J, Cheng J, and Wu M (2017) Identification of morin as an agonist of imidazoline I-3 receptor for insulin secretion in diabetic rats. Naunyn-Schmiedebergs Archives of Pharmacology 390(10): 997-1003. https://doi.org/10.1007/s00210-017-1399-7 [PubMed]

Lowry J and Brown J (2014) Significance of the imidazoline receptors in toxicology. Clinical Toxicology 52(5): 454-469. https://doi.org/10.3109/15563650.2014.898770 [PubMed]

Mahmoudi J, Majdi A, Lattanzi S, Napoli MD, Bershad EM, Rodrigues CM, and Divani AA (2018) Imidazoline receptor agonists for managing hypertension may hold promise for treatment of intracerebral hemorrhage. Current Molecular Medicine 18 (4): 241-251. https://doi.org/10.2174/1566524018666180926163712 [PubMed]

Maslov MY, Wei AE, Pezone MJ, Edelman ER, and Lovich MA (2015) Vascular dilation, tachycardia, and increased inotropy occur sequentially with increasing epinephrine dose rate, plasma and myocardial concentrations, and cAMP. Heart, Lung Circulation 24(9): 912–918.https://doi.org/1016/j.hlc.2015.02.012 [PubMed]

Maslov MD, Abraham EW, Pezone MJ, Edelman ER, and Lovich MA (2015)Vascular dilation, tachycardia, and increased inotropy occur sequentially with increasing epinephrine dose rate, plasma and myocardial concentrations. Heart Lung Circulation 24(9): 912-918.https://doi.org/10.1016/j.hlc.2015.02.012 [PubMed]

Messerli F (2000) Moxonidine: a new and versatile antihypertensive drug. Journal of Cardiovascular Pharmacology 35: 53-56. https://doi.org/10.1097/00005344-200000004-00007 [PubMed]

Miralles A, Olmos G, Sastre M, Barturen F, Martin I, and Garcia-Sevilla JA (1993) Discrimination and pharmacological characterization of I2-imidazoline sites with [3H] idazoxan and alpha-2 adrenoceptors with [3H] RX821002 (2-methoxy idazoxan) in the human and rat brains. Journal Pharmacology Experimental Therapeutics 264(3): 1187–1197. [PubMed]

Moreira TS, Takakura AC, Menani JV, and Colombari E (2007) Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine. European Journal of Pharmacology 563 (1-3): 164-171. https://doi.org/10.1016/j.ejphar.2007.02.002 [PubMed]

Morgan N, Chan S, Mourtada M, Monks LK, and Ramsden CA (1999) Imidazolines and pancreatic hormone secretion. Annals of the New York Academy of Sciences 881: 217–228. https://doi.org/10.1111/j.1749-6632.1999.tb09364.x [PubMed]

Morgan N, Cooper E, Squires P, Hills C, Parker C, and Hudson A (2003) Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells. Annals of the New York Academy of Sciences 1009: 167–174. https://doi.org/10.1196 / annals.1304.019 [PubMed]

Mukaddam-Daher S and Gutkowska J (2004) Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Brazilian Journal of Medical and Biological Research 37(8): 1239-1245. https://doi.org/10.1590/s0100-879x2004000800015 [PubMed]

Nguyen HD, Choo YY, Nguyen TD, Nguyen HN, Chau VM, and Lee J-H (2016) 7-methoxy-(9H-β-carbolin-1-il)-(E)-1-propenoic acid, a β-carboline alkaloid from Eurycoma longifolia, exhibits anti-inflammatory effects by activating the Nrf2 heme oxygenase-1 pathway. Journal of Cellular Biochemisty 117(3): 659-670. https://doi.org/10.1002/jcb.25315 [PubMed]

Proschaev KI, Ilnitsky A, Bessarabov VI, Pavlova TV, Kvetnaya TV, Bolkhovitina OA, and Pozdnyakova NM (2012) Molecular foundations of the development and progression of chronic heart failure in the elderly and senile age. Molecular Medicine 6: 60-63.

Radwanska A, Dlugokecka J, Wasilewski R, and Kaliszan R (2009) Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria. Journal of Physiology and Pharmacology 60(1): 131-142. [PubMed]

Ristovska E, Genadieva-Dimitrova M, Todorovska B, Milivojevic V, Rankovic I, Samardziski I, and Bojadzioska M (2006) The role of endothelial dysfunction in the pathogenesis of pregnancy-related pathological conditions: A review. Prilozi 44(2): 113-137. https://doi.org/2478/prilozi-2023-0032 [PubMed]

Ruffolo R, Yaden E, and Waddell J (1982) Stereochemical requirements of alpha-2 adrenergic receptors for alpha-methyl substituted phenethylamines. Journal of Pharmacology and Experimental Therapeutics 222(3): 645-651. https://doi.org/1016/0024-3205(82)90067-4 [PubMed]

Siwik DA, Chang DL, and Colucci WS (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circulation Research 86(12): 1259-1265. https://doi.org/10.1161/01.res.86.12.1259 [PubMed]

Smyth D and Penner S (1999) Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Annals of the New York Academy of Sciences 881: 344-357. https://doi.org/10.1111/j.1749-6632.1999.tb09378.x [PubMed]

Stepenko YuV, Shmigerova VS, Kostina DA, Shcheblykina OV, Zhernakova NI, Solin AV, Koroleva NV, Markovskaya VA, Dudnikova OV, and Bolgov AA (2024) Study of the neuroprotective properties of the heteroreceptor EPOR/CD131 agonist of peptide structure in tau-proteinopathy modeling. Research Results in Pharmacology 10(2): 41–47. [in Russian]

Strausberg R, Feingold E, Grouse L, Derge JG, Klausner DR, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceeding of the National Academy of Sciences of the United States of America 99(26): 16899–16903. https://doi.org/10.1073/pnas.242603899 [PubMed]

Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E (2001) Lowering of microalbu minuria in diabetic patients by sympaticoplegic agent: novel approach to prevent progression of diabetic nephropathy. Journal of the American Society of Nephrology 12: 602-605. https://doi.org/10.1681 /ASN.V123602 [PubMed]

Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M (2000) The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. Journal of the American College of Cardiology 35(2): 398-404. https://doi.org/10.1016/s0735-1097(99)00565-3 [PubMed]

Velliquette RA, Kossover R, Previs SF, and Ernsberger P (2006) Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome. Naunyn-Schmiedebergs Archives of Pharmacology 372(4): 300–312. https://doi.org/1007/s00210-005-0024-3 [PubMed]

Wang X and He B (2024) Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm 5(8): e651. https://doi.org/1002/mco2.651 [PubMed]

Zhang J and Abdel-Rahman AA (2006) Nischarin as a functional imidazoline (I1) receptor. FEBS Letters 580: 3070–3074. https://doi.org/10.1016/j.febslet.2006.04.058 [PubMed]

Вклад авторов

Юлия В. Степенко, Белгородский государственный национальный исследовательский университет

Candidate of Medical Sciences, Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: stepenko@bsu.edu.ru; ORCID ID: https://orcid.org/0000-0002-7414-7326. The author took part in the design of the study, in conducting experimental work and analyzing the material.

Олеся В. Щеблыкина, Белгородский государственный национальный исследовательский университет

Candidate of Medical Sciences, Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: sheolvi31@gmail.com; ORCID ID: https://orcid.org/0000-0003-0346-9835. The author edited the text of the article.

Анна А. Пересыпкина, Белгородский государственный национальный исследовательский университет

Habil. Sci. (Biology), Full Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: peresypkina_a@bsuedu.ru; ORCID ID: https://orcid.org/0000-0003-2829-9860. The author edited the text of the manuscript.

Вероника С. Шмигерова, Белгородский государственный национальный исследовательский университет

Candidate of Biology Sciences, Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: beliaeva@yandex.ru; ORCID ID: https://orcid.org/0000-0003-2941-0241. The author analyzed the results and edited the text of the article.

Йомна Ахмед, Белгородский государственный национальный исследовательский университет

Medical student, Belgorod State National Research University, Belgorod, Russia; e-mail: 1444711@bsuedu.ru; ORCID ID: https://orcid.org/0009-0001-1841-7088. The author was engaged in structuring the article and arranging the references.

Татьяна А. Денисюк, Курский государственный медицинский университет

Doctor Habil. of Medical Sciences, Associate Professor of the Department of Pharmacology, Kursk State Medical University, Ministry of Health of Russia, Kursk, Russia; е-mail: denitatyana@yandex.ru; ORCID ID: https://orcid.org/0000-0003-0974-4818. The author edited the text of the article.

Антон П. Даниленко, Белгородский государственный национальный исследовательский университет

Postgraduate student of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: 1190540@bsu.edu.ru; ORCID ID: https://orcid.org/0009-0001-2419-8109. The author edited the text of the article.

Никита С. Ляпкалов, Белгородский государственный национальный исследовательский университет

Medical student, Belgorod State National Research University, Belgorod, Russia; e-mail: lyapkalovns@gmail.com; ORCID ID: https://orcid.org/0009-0004-7208-5055. The author was engaged in developing the concept and lite.

Елена А. Шмыкова, Белгородская областная клиническая больница святителя Иоасафа

Clinical pharmacologist of St. Joasaph Belgorod Regional Clinical Hospital, Belgorod, Russia; e-mail: elenasm79@mail.ru; ORCID ID: https://orcid.org/0009-0005-2983-0619. The author analyzed the literature.

Людмила М. Даниленко, Белгородский государственный национальный исследовательский университет

Doc. Sci. (Pharmacy), Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia; e-mail: Danilenko_L@bsu.edu.ru; ORCID ID: https://orcid.org/0000-0001-6101-8712. The author generated the idea of research and was engaged in developing the concept, analysing literature and writing the paper.

 

Опубликован

30.09.2025

Как цитировать

Stepenko YV, Shcheblykina OV, Peresypkina AA, Shmigerova VS, Akhmed YY, Denisyuk TA, Danilenko AP, Lyapkalov NS, Shmykova EA, Danilenko LM (2025) Nonclassical cardiovascular effects of imidazoline receptor agonists. Research Results in Pharmacology 11(3): 77–86. https://doi.org/10.18413/rrpharmacology.11.640

Выпуск

Раздел

Фармакологические обзоры

Наиболее читаемые статьи этого автора (авторов)